Podemos definir a melhor métrica para manejo do diabetes? HbA1c ou tempo no alvo?

American Diabetes Association. 13. Children and adolescents: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020;43(Suppl 1):S163-S182.
Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42:1593-1603.
Beck RW, Connor CG, Mullen DM, et al. The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading. Diabetes Care. 2017;40:994-999.
Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019;42:400-405.
Beck RW, Bergenstal RM, Cheng P, et al. The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol. 2019;13:614-626.
Clarke SF, Foster JR. A history of blood glucose meters and their role in self-monitoring of diabetes mellitus. Br J Biomed Sci. 2012;69:83-93.
Cleary PA, Orchard TJ, Genuth S, et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes. 2006;55:3556-3565.
Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40:1631-1640.
Das AK, Shah S. History of diabetes: from ants to analogs. J Assoc Physicians India. 2011;59 Suppl:6-7.
DCCT/EDIC Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999;22:99-111.
DCCT/EDIC Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563-2569.
EDIC Research Group. Retinopathy and nephropathy in patients with Type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381-389.
DCCT/EDIC Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159-2167.
DCCT/EDIC Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348:2294-2303.
DiMeglio LA, Acerini CL, Codner E, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatr Diabetes. 2018;19 Suppl 27:105-114.
Herman WH, Cohen RM. Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab. 2012;97:1067-1072.
Himsworth HP. Management of diabetes mellitus. Br Med J. 1936;2:137-141.
Hirsch IB. Introduction: history of glucose monitoring. 2018 Aug. In: Role of Continuous Glucose Monitoring in Diabetes Treatment. Arlington (VA): American Diabetes Association; 2018 Aug. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538968/. Accessed on March 19, 2020.
Lenters-Westra E, Schindhelm RK, Bilo HJ, et al. Haemoglobin A1c: historical overview and current concepts. Diabetes Res Clin Pract. 2013;99:75-84.
Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31:1473-1478.
National Institute for Health and Care Excellence. NICE guideline [NG28]. Type 2 diabetes in adults: management. December 2015. Available at: https://www.nice.org.uk/guidance/ng28
National Institute for Health and Care Excellence. Diabetes (type 1 and type 2) in children and young people: diagnosis and management. August 2015. Available at: https://www.nice.org.uk/guidance/ng18
Sacks DB. Correlation between hemoglobin A1c (HbA1c) and average blood glucose: can HbA1c be reported as estimated blood glucose concentration? J Diabetes Sci Technol. 2007;1:801-803.
The Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.

A WebMD Global exige que todos os indivíduos que tenham controle sobre o conteúdo de suas atividades educativas declarem qualquer relação financeira relevante ocorrida nos últimos 12 meses que possa criar um conflito de interesses.

Faculdade

Dr. Domingos A. Malerbi, PhD, MD

Faculdade de Medicina da Universidade de São Paulo
Endocrinologista do Corpo Clínico
Hospital Israelita Albert Einstein
São Paulo, Brasil
Presidente da Sociedade Brasileira de Diabetes 2020/2021

Disclosures

Declaração: Dr. Domingos A. Malerbi, PhD, MD, declarou as seguintes relações financeiras relevantes:
Atuou como conselheiro ou consultor para: Boehringer Ingelheim; Sanofi

Dr. Luís Eduardo Calliari, MD

Faculdade de Ciências Médicas da Santa Casa de São Paulo
Departamento de Pediatria
Unidade de Endocrinologia Pediátrica e Ambulatório de Diabetes Pediátrico
São Paulo, Brasil

Disclosures

Declaração: Dr. Luís Eduardo Calliari, MD, declarou as seguintes relações financeiras relevantes:
Atuou como conselheiro ou consultor para: Abbott; Novo Nordisk; Medtronic; Sanofi
Atuou como palestrante ou integrante do painel de palestrantes para: Abbott; Lilly; Novo Nordisk; Medtronic; Pfizer; Roche; Sanofi

Dr. Márcio Krakauer, MD

Responsável pela Associação de Diabetes do ABC
Assessor da presidência e coordenador do Departamento de Tecnologia da Sociedade Brasileira de Diabetes

Disclosures

Declaração: Dr. Márcio Krakauer, MD, não declarou nenhuma relação financeira relevante.

Editora

Anne G. Le, PharmD

Diretora sênior de Educação Médica da Medscape, LLC

Disclosures

Declaração: Anne G. Le, PharmD, não declarou nenhuma relação financeira relevante.

Rita Moreira da Silva, PhD, PharmD

Diretora de Educação Médica da Medscape Global, LLC

Disclosures

Declaração: Rita Moreira da Silva PhD, PharmD, não declarou nenhuma relação financeira relevante.

Revisor de conteúdo

Robert Morris, PharmD

Diretor Associado, acreditação e adequação, Medscape, LLC

Disclosures

Declaração: Robert Morris, PharmD, declarou as seguintes relações financeiras relevantes:
Atuou como conselheiro ou consultor para a empresa: ViiV Healthcare
Possui ações, opções de ações, ou dividendos de: GlaxoSmithKline